Alivus Life Sciences Q1 FY27: Profit up 32% on 6% sales

Key takeaway from Q1 FY27

Alivus Life Sciences reported a strong Q1 FY27 on profitability, even as revenue growth stayed in single digits. Standalone revenue from operations rose 6.4% year-on-year to ₹640.41 crore from ₹601.80 crore. Standalone profit after tax increased 31.8% year-on-year to ₹160.08 crore from ₹121.54 crore. The company attributed the performance to a highly favorable product mix and operational efficiencies. A key driver highlighted was the non-GPL segment, which grew 26.5% year-on-year. The quarter also showed a sharp step-up in margins, supported by operating leverage and rationalised input costs. Alivus said it remained net debt-free and ended the quarter with sizable cash reserves.

How revenue growth was driven

The revenue increase was supported by strong growth in the non-GPL business, which expanded 26.5% year-on-year. The company’s disclosure positioned the product mix as a material contributor to the profit jump relative to revenue growth. Revenue from operations for Q1 FY27 stood at ₹640.41 crore, compared with ₹601.80 crore in the corresponding period last year. Separately, total income for the quarter was reported at ₹662.82 crore, helped by other income. Other income rose to ₹22.40 crore from ₹8.99 crore in Q1 FY26, as per the figures provided. Total expenses were ₹450.59 crore, up marginally from ₹447.85 crore, indicating cost discipline during the quarter. This combination of steady sales growth, higher other income, and controlled expenses supported earnings expansion.

Margin expansion and EBITDA details

EBITDA for the quarter came in at ₹234.10 crore, up 29.1% year-on-year. EBITDA margin expanded by 650 basis points year-on-year to 36.6%, which the company linked to better operating leverage and rationalised input costs. The margin improvement was notable versus the prior-year period, given the smaller rise in revenue. Profit before tax was reported at ₹212.22 crore versus ₹162.98 crore a year earlier, a 30.2% increase. Basic earnings per share increased to ₹13.04 from ₹9.91 in the previous year period. The results underline that profitability was driven more by mix and cost efficiencies than by volume-led revenue acceleration. Alivus also referenced the quarter’s performance as being aided by “excellent operational efficiencies” in its summary.

Cash, balance sheet position, and free cash flow

Alivus stated it remained net debt-free during the quarter. Free cash flow generation in Q1 FY27 was ₹90.10 crore. Cash and cash equivalents at the end of the quarter were reported at ₹880.20 crore. The company’s cash position, alongside net debt-free status, adds flexibility for operations and planned initiatives. In the provided historical comparison, Q1 FY26 free cash flow was noted at ₹100.00 crore with cash and cash equivalents (including short term investments) of ₹660.40 crore as of June 30, 2025. While the quarter-on-quarter comparisons were not fully detailed in the text, the disclosed figures show continued cash generation and a higher reported cash balance in the latest quarter. Investors often track this combination of cash conversion and balance sheet strength when margins expand.

Board meeting and earnings call schedule

The company scheduled a board meeting for July 30, 2026, to consider and approve the Q1 FY27 unaudited financial results. An earnings call for Q1 FY2026-27 was scheduled for July 31, 2026, from 8:30 AM to 9:30 AM IST. The call was described as accessible via universal dial-in numbers in India and via international toll-free and toll numbers across regions including Australia, Canada, China, Hong Kong, Japan, Singapore, the UK, and the USA. The universal dial-in numbers listed for India were +91 22 6280 1564 and +91 22 7115 8394. Such calls typically focus on segment performance, margin drivers, and near-term operating priorities, though the details of management commentary were not included in the provided text. The schedule places the discussion immediately after the results approval timeline referenced.

Market snapshot and stock data points cited

The provided text included multiple market price references around the results window. A “Quick Details” section listed a CMP of ₹1,101.2. Another line cited the stock “currently trading at around ₹1,102.80,” while a separate Q&A stated a current share price of ₹1,147.3. Elsewhere, a CMP of ₹1,179 was cited alongside a market capitalisation of ₹14,232 crore and a price-to-earnings multiple of 25.2. The same block mentioned a 12-month target range of ₹1,190 to ₹1,344 as a “Uniresearch Estimate.” These figures reflect snapshots from different timestamps in the text, rather than a single consolidated close. The article text also listed listed peers including Cipla, Sun Pharmaceutical Industries, and Divi’s Laboratories, without drawing performance conclusions.

Recent quarterly context provided in the data

The text also shared “previous quarter” figures as context: revenue of ₹689.10 crore, PAT of ₹162.70 crore, and an EBITDA margin of 34.4%. A separate quarterly table (figures in crore) showed net sales of ₹689.12 crore in Mar 2026 and ₹601.85 crore in Jun 2025, aligning broadly with the year-ago base referenced for Q1. The same table listed profit after tax of ₹162.66 crore for Mar 2026 and ₹121.54 crore for Jun 2025. This backdrop helps explain why the year-on-year comparison shows strong improvement in profitability, while sequential patterns may differ depending on product mix and other income. The text also noted investor focus on the launch of the Solapur greenfield facility in Q2 FY27 and a target of sustaining EBITDA margins above 30%.

Summary table of reported Q1 performance

Why the results matter for investors tracking FY27

The quarter shows a clear gap between revenue growth and profit growth, implying a mix-led and efficiency-led earnings improvement. The stated 36.6% EBITDA margin, alongside a net debt-free balance sheet, frames the results as a margin-and-cash story. The sharp rise in other income also contributed to the increase in total income, based on the figures provided. The non-GPL segment growth of 26.5% year-on-year was singled out as a key operational driver in the company’s snapshot. With an earnings call scheduled for July 31, investors will look for further clarity on segment performance and the sustainability of margin levels above 30%, a target referenced in the text. Separately, the text mentioned attention on the Solapur greenfield facility launch in Q2 FY27, which may be a discussion point given its timing in the current fiscal year. Any forward-looking view beyond these stated items was not included in the provided material.

Conclusion

Alivus Life Sciences’ Q1 FY27 results showed PAT rising to ₹160.08 crore on revenue of ₹640.41 crore, with EBITDA margin expanding to 36.6% and free cash flow of ₹90.10 crore. The board meeting on July 30, 2026 and the earnings call on July 31, 2026 are the next scheduled touchpoints for investors seeking more details on drivers such as product mix, the non-GPL business, and margin discipline.